Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 1, 2005, Pages 5-12

  Takada, M ^a   Goto, T ^b   Kotake, T ^a   Saito, M ^c   Kawato, N ^a   Nakai, M ^d   Gunji, T ^e   Shibakawa, M ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

Author keywords

Antiarrhythmic drug; Digoxin; Dosing regimen; Prescription; Therapeutic drug monitoring

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; APRINDINE; CIBENZOLINE; DIGOXIN; DISOPYRAMIDE; FLECAINIDE; MEXILETINE; PILSICAINIDE; PIRMENOL;

ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MONITORING; HEART ARRHYTHMIA; HUMAN; JAPAN; MAJOR CLINICAL STUDY; PRESCRIPTION; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG USE; MEDICAL RECORD; METHODOLOGY; MULTICENTER STUDY; STATISTICS;

ANTI-ARRHYTHMIA AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG UTILIZATION REVIEW; HOSPITAL RECORDS; HUMANS; JAPAN; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG;

EID: 23844536551     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2004.00612.x     Document Type: Article

References (40)

1. van Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA (1999) Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Therapeutic Drug Monitoring, 21, 63-73.
2. Welty TE, Copa AK (1994) Impact of vancomycin therapeutic drug monitoring on patient care. Annals of Pharmacotherapy, 28, 1335-1339.
3. Ried LD, Horn JR, McKenna DA (1990) Therapeutic drug monitoring reduces toxic drug reactions: a meta-analysis. Therapeutic Drug Monitoring, 12, 72-78.
4. Koren G, Soldin S, MacLeod SM (1985) Organization and efficacy of a therapeutic drug monitoring consultation service in a pediatric hospital. Therapeutic Drug Monitoring, 7, 295-298.
5. Matzuk MM, Shlomchik M, Shaw LM (1991) Making digoxin therapeutic drug monitoring more effective. Therapeutic Drug Monitoring, 13, 215-219.
6. Welty TE, Copa AK (1994) Impact of vancomycin therapeutic drug monitoring on patient care. Annals of Pharmacotherapy, 28, 1335-1339.
7. Niarchos AP (1976) Disopyramide: serum level and arrhythmia conversion. American Heart Journal, 92, 57-64.
8. Campbell NPS, Pantridge JF, Adgey AAJ (1978) Long-term oral antiarrhythmic therapy with mexiletine. British Heart Journal, 40, 796-801.
9. Lui HK, Lee G, Dietrich P et al. (1982) Flecainide-induced QT prolongation and ventricular tachycardia. American Heart Journal, 103, 567-569.
10. Spivack C, Gottlieb S, Miura DS, Somberg JC (1984) Flecainide toxicity. American Journal Cardiology, 53, 329-330.
11. Ray J (1990) Flecainide: what are we measuring? Therapeutic Drug Monitoring, 12, 416.
12. Watson ID (1991) Flecainide: what are we measuring? Therapeutic Drug Monitoring, 13, 86.
13. Brazzell RK, Aogaichi K, Heger JJ, Somberg JC, Carliner NH, Morganroth J (1984) Cibenzoline plasma concentration and antiarrhythmic effect. Clinical Pharmacology and Therapeutics, 35, 307-316.
14. Brazzell RK, Colburn WA, Aogaichi K et al. (1985) Pharmacokinetics of oral cibenzoline in arrhythmia patients. Clinical Pharmacokinetics, 10, 178-186.
15. Smith TW, Haber E (1970) Digoxin intoxication: the relationship of clinical presentation to serum digoxin concentration. Journal of Clinical Investigation, 49, 2377-2386.
16. Smith TW (1975) Digitalis toxicity: epidemiology and clinical use of serum concentration measurements. The American Journal of Medicine, 58, 470-476.
17. Beller GA, Smith TW, Abelman WH, Haber E, Hood WB (1971) Digitalis intoxication. A prospective clinical study with serum level correlations. The New England Journal of Medicine, 284, 989-997.
18. Doherty JE, de Soyza N, Kane JJ, Bissett JK, Murphy ML (1978) Clinical pharmacokinetics of digitalis glycosides. Progress in Cardiovascular Diseases, 21, 141-158.
19. Campbell TJ, Williams KM (1998) Therapeutic drug monitoring: antiarrhythmic drugs. British Journal of Clinical Pharmacology, 46, 307-319.
20. Johnson BF, Haffajee CI, Woodman T, Sloan LK (1988) The relation of the kinetics of pirmenol to its antiarrhythmic efficacy. Journal of Clinical Pharmacology, 28, 401-405.
21. Van Durme JP, Bogaert MG, Rosseel MT (1974) Therapeutic effectiveness and plasma levels of aprindine, a new antidysrhythmic drug. European Journal of Clinical Pharmacology, 7, 343-346.
22. Fasola AF, Noble RJ, Zipes DP (1977) Treatment of recurrent ventricular tachycardia and fibrillation with aprindine. American Journal of Cardiology, 39, 903-909.
23. Monk JP, Brogden RN (1990) Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs, 40, 374-411.
24. Fasola AF, Carmichael R (1974) The pharmacology and clinical evaluation of aprindine a new antiarrhythmic agent. Acta Cardiologica, 18(Suppl.), 317-333.
25. Nakashima M, Kanakaru M, Uematsu T et al. (1989) Phase I study of SUN 1165, a novel antiarrhythmic agent No.1: Single dose study (in Japanese). Journal of Clinical Therapeutics and Medicine, 5, 661-678.
26. Anderson JL, Stewart JR, Perry BA et al. (1981) Oral flecainide acetate for the treatment of ventricular arrhythmias. The New England Journal of Medicine, 305, 473-477.
27. Rotmensch HH, Belhassen B, Swanson BN et al. (1984) Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Annals of Internal Medicine, 101, 462-469.
28. Singh BN, Venkatesh N, Nademanee K, Josephson MA, Kannan R (1989) The historical development, cellular electrophysiology and pharmacology of amiodarone. Progress Cardiovascular Diseases, 31, 249-280.
29. Counihan PJ, McKenna WJ (1989) Low-dose amiodarone for the treatment of arrhythmias in hypertrophic cardiomyopathy. Journal of Clinical Pharmacology, 29, 436-438.
30. Mooradian AD (1988) Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. Clinical Pharmacokinetics, 15, 165-179.
31. Takada M, Shibakawa M (2001) Efficacy of therapeutic drug monitoring in prevention of hypoglycemia caused by cibenzoline. European Journal of Clinical Pharmacology, 57, 695-700.
32. Lieberman R, Nelson R (1993) Dose-response and concentration-response relationships: clinical and regulatory perspectives. Therapeutic Drug Monitoring, 15, 498-502.
33. D'Angio RG, Stevenson JG, Lively BT, Morgan JE (1990) Therapeutic drug monitoring: improved performance through educational intervention. Therapeutic Drug Monitoring, 12, 173-181.
34. Gardner DM, Hardy BG (1990) Cost-effectiveness of therapeutic drug monitoring. The Canadian Journal of Hospital Pharmacy, 43, 7-12.
35. Fernandez de Gatta MD, Calvo MV, Hernandez JM, Caballero D, San Miguel JF, Dominguez-Gil A (1996) Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clinical Pharmacology and Therapeutics, 60, 332-340.
36. Bertino JS Jr, Rodvold KA, Destache CJ (1994) Cost considerations in therapeutic drug monitoring of aminoglycosides. Clinical Pharmacokinetics, 26, 71-81.
37. Destache CJ (1993) Use of therapeutic drug monitoring in pharmacoeconomics. Therapeutic Drug Monitoring, 15, 608-610.
38. Preskorn SH, Fast GA (1991) Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. Journal of Clinical Psychiatry, 52(Suppl.), 23-33.
39. Preskorn SH, Dorey RC, Jerkovich GS (1988) Therapeutic drug monitoring of tricyclic antidepressants. Clinical Chemistry, 34, 822-828.
40. Eilers R (1995) Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness. Clinical Pharmacokinetics, 29, 442-450.